Compare · CNMD vs TMDX
CNMD vs TMDX
Side-by-side comparison of CONMED Corporation (CNMD) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNMD and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $3.25B, about 2.1x CNMD ($1.53B).
- TMDX has hit the wire 5 times in the past 4 weeks while CNMD has been quiet.
- TMDX has more recent analyst coverage (19 ratings vs 16 for CNMD).
- Company
- CONMED Corporation
- TransMedics Group Inc.
- Price
- -
- -
- Market cap
- $1.53B
- $3.25B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 1987
- 2019
- News (4w)
- 0
- 5
- Recent ratings
- 16
- 19
CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest CNMD
- SEC Form 10-Q filed by CONMED Corporation
- CONMED Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
- CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula
- CONMED Corporation to Participate in the Society of Robotic Surgery Annual Meeting
- SEC Form 4 filed by Executive Vice President & CFO Gallagher John E
- New insider Gallagher John E claimed no ownership of stock in the company (SEC Form 3)
- BMO Capital Markets initiated coverage on CONMED with a new price target
- SEC Form 4 filed by Director Martin Celine Christine
- SEC Form 4 filed by Director Mirviss Jeffrey B.
Latest TMDX
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
- UBS initiated coverage on TransMedics Group with a new price target
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)